Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.50 |
| ▸ | CDK2 | P24941 | 8/20 | 0.50 |
| ▸ | CCNK | O75909 | 5/20 | 0.50 |
| ▸ | CDK9 | P50750 | 5/20 | 0.50 |
| ▸ | CCND3 | P30281 | 4/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26161918 | 0.89 | CCNA2 (0.63) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL30394901 | 0.89 | CCNA2 (0.63) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL21600781 | 0.89 | KMT2A (0.52) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL264974 | 0.87 | TP53 (0.47) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL30833794 | 0.86 | GAA (0.42) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL22828247 | 0.86 | GAA (0.42) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL16684776 | 0.86 | LRRK2 (0.49) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL264920 | 0.84 | ALDH1A1 (0.46) | TP53TSHRRAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL22520101 | 0.83 | LRRK2 (0.38) | LRRK2CCNA2CDK2CCNKCDK9 | |
| SCHEMBL27751334 | 0.83 | MAPT (0.56) | LRRK2CDK9HTTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LRRK2 467/4885CCNA2 1906/4885CDK2 126/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | LRRK2 428/4885CCNA2 2014/4885CDK2 105/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LRRK2 467/4885CCNA2 1906/4885CDK2 126/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LRRK2 467/4885CCNA2 1906/4885CDK2 126/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LRRK2 467/4885CCNA2 1906/4885CDK2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.